Nobutaka Nakamura
- Clinical Biochemistry top 1%
- Advanced Glycation End Products research 14
-
- Natural Antidiabetic Agents Studies 4
- Diabetes Treatment and Management 3
- Diabetes, Cardiovascular Risks, and Lipoproteins 2
- Nephrology top 5%
- Chronic Kidney Disease and Diabetes 8
- Acute Kidney Injury Research 2
- Dialysis and Renal Disease Management 1
-
- Acute Ischemic Stroke Management 2
Nobutaka Nakamura
19 papers receiving 856 citations
Peers
Comparison fields: 5 of 79
- Clinical Biochemistry 363
- Endocrinology, Diabetes and Metabolism 398
- Nephrology 155
- Neurology 43
- Biochemistry 30
Countries citing papers authored by Nobutaka Nakamura
This map shows the geographic impact of Nobutaka Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobutaka Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobutaka Nakamura more than expected).
Fields of papers citing papers by Nobutaka Nakamura
This network shows the impact of papers produced by Nobutaka Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobutaka Nakamura. The network helps show where Nobutaka Nakamura may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nobutaka Nakamura, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 2 | |
| 2 | 2020 | 5 | |
| 3 | 2019 | 11 | |
| 4 | 2018 | 23 | |
| 5 | 2018 | 38 | |
| 6 | 2017 | 105 | |
| 7 | 2017 | 24 | |
| 8 | 2016 | 60 | |
| 9 | 2016 | 73 | |
| 10 | 2015 | 45 | |
| 11 | 2015 | 136 | |
| 12 | 2015 | 183 | |
| 13 | 2015 | 60 | |
| 14 | 2014 | 13 | |
| 15 | 2014 | 21 | |
| 16 | 2003 | 17 | |
| 17 | 1998 | 40 | |
| 18 | 1998 | 4 | |
| 19 | [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy]. | 1995 | 2 |
About Nobutaka Nakamura
Nobutaka Nakamura is a scholar working on Clinical Biochemistry, Nephrology and Endocrinology, Diabetes and Metabolism, having authored 19 papers that have together received 862 indexed citations. Recurring topics across this work include Advanced Glycation End Products research (14 papers), Chronic Kidney Disease and Diabetes (8 papers), Natural Antidiabetic Agents Studies (4 papers), Diabetes Treatment and Management (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers), Acute Ischemic Stroke Management (2 papers), Acute Kidney Injury Research (2 papers) and Dialysis and Renal Disease Management (1 paper). The work is most often cited by research in Clinical Biochemistry (363 citations), Endocrinology, Diabetes and Metabolism (398 citations) and Nephrology (155 citations). Nobutaka Nakamura has collaborated with scholars based in Japan and United States. Frequent co-authors include Sho‐ichi Yamagishi, Takanori Matsui, Ayako Ojima, Yoshinori Nishino, Yuichiro Higashimoto, Kei Fukami, Kuniyoshi Kaseda, Yuri Nishino, Yuji Ishibashi and Seiya Okuda. Their work appears in journals such as Diabetes, International Journal of Molecular Sciences and Diabetic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.